Definitive Carbon-Ion Radiation Therapy for Locally Advanced Sinonasal Malignant Tumors: Subgroup Analysis of a Multicenter Study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS)

Japan Carbon-Ion Radiation Oncology Study Group

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To evaluate the safety and efficacy of carbon-ion radiation therapy (C-ion RT) for locally advanced sinonasal malignant tumors in a multicenter retrospective study (J-CROS 1402 HN). Methods and Materials: Clinical data were collected for patients who had sinonasal malignant tumors of stage N0-1M0 and received C-ion RT at 4 institutions in Japan between November 2003 and December 2014. Of the 458 patients, 393 had naïve tumors and 65 had recurrent tumors. The tumors were located in the nasal cavity (n = 263), maxillary sinus (n = 109), ethmoid sinus (n = 71), and other locations (n = 15). The histologic types were mucosal melanoma (n = 221, 48%), adenoid cystic carcinoma (n = 122, 27%), squamous cell carcinoma (n = 31, 7%), olfactory neuroblastoma (n = 30, 7%), adenocarcinoma (n = 21, 5%), and other types (n = 33, 7%). Of the 458 patients, 300 (66%) had T4 tumors. All patients received definitive C-ion RT. Results: The median follow-up period was 25.2 months for all patients (range, 1.4-132.3 months). The 2-year overall survival and local control rates were 79.6% and 84.1%, respectively. As analyzed according to histology, the 2-year overall survival rate was 68.0% for mucosal melanoma, 96.8% for adenoid cystic carcinoma, 70.0% for squamous cell carcinoma, 96.7% for olfactory neuroblastoma, and 89.7% for adenocarcinoma. Regarding late toxicities, 17% of patients developed grade 3 and 4 toxicities, of which visual impairment was the most common. Conclusion: The results of our multicenter study have demonstrated that C-ion RT can provide excellent clinical outcomes with acceptable late toxicities in patients who have locally advanced sinonasal malignant tumors.

Original languageEnglish
Pages (from-to)353-361
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume102
Issue number2
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Heavy Ion Radiotherapy
Radiation Oncology
subgroups
Multicenter Studies
radiation therapy
Japan
tumors
Carbon
Ions
carbon
radiation
cancer
Neoplasms
Olfactory Esthesioneuroblastoma
toxicity
ions
sinuses
Adenoid Cystic Carcinoma
Squamous Cell Carcinoma
Melanoma

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{29d645b1de8043ce8339c8cb12e79f90,
title = "Definitive Carbon-Ion Radiation Therapy for Locally Advanced Sinonasal Malignant Tumors: Subgroup Analysis of a Multicenter Study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS)",
abstract = "Purpose: To evaluate the safety and efficacy of carbon-ion radiation therapy (C-ion RT) for locally advanced sinonasal malignant tumors in a multicenter retrospective study (J-CROS 1402 HN). Methods and Materials: Clinical data were collected for patients who had sinonasal malignant tumors of stage N0-1M0 and received C-ion RT at 4 institutions in Japan between November 2003 and December 2014. Of the 458 patients, 393 had na{\"i}ve tumors and 65 had recurrent tumors. The tumors were located in the nasal cavity (n = 263), maxillary sinus (n = 109), ethmoid sinus (n = 71), and other locations (n = 15). The histologic types were mucosal melanoma (n = 221, 48{\%}), adenoid cystic carcinoma (n = 122, 27{\%}), squamous cell carcinoma (n = 31, 7{\%}), olfactory neuroblastoma (n = 30, 7{\%}), adenocarcinoma (n = 21, 5{\%}), and other types (n = 33, 7{\%}). Of the 458 patients, 300 (66{\%}) had T4 tumors. All patients received definitive C-ion RT. Results: The median follow-up period was 25.2 months for all patients (range, 1.4-132.3 months). The 2-year overall survival and local control rates were 79.6{\%} and 84.1{\%}, respectively. As analyzed according to histology, the 2-year overall survival rate was 68.0{\%} for mucosal melanoma, 96.8{\%} for adenoid cystic carcinoma, 70.0{\%} for squamous cell carcinoma, 96.7{\%} for olfactory neuroblastoma, and 89.7{\%} for adenocarcinoma. Regarding late toxicities, 17{\%} of patients developed grade 3 and 4 toxicities, of which visual impairment was the most common. Conclusion: The results of our multicenter study have demonstrated that C-ion RT can provide excellent clinical outcomes with acceptable late toxicities in patients who have locally advanced sinonasal malignant tumors.",
author = "{Japan Carbon-Ion Radiation Oncology Study Group} and Masashi Koto and Yusuke Demizu and Saitoh, {Jun ichi} and Hiroaki Suefuji and Hiroshi Tsuji and Tomoaki Okimoto and Tatsuya Ohno and Yoshiyuki Shioyama and Hiroaki Ikawa and Kenji Nemoto and Takashi Nakano and Tadashi Kamada",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.ijrobp.2018.05.074",
language = "English",
volume = "102",
pages = "353--361",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Definitive Carbon-Ion Radiation Therapy for Locally Advanced Sinonasal Malignant Tumors

T2 - Subgroup Analysis of a Multicenter Study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS)

AU - Japan Carbon-Ion Radiation Oncology Study Group

AU - Koto, Masashi

AU - Demizu, Yusuke

AU - Saitoh, Jun ichi

AU - Suefuji, Hiroaki

AU - Tsuji, Hiroshi

AU - Okimoto, Tomoaki

AU - Ohno, Tatsuya

AU - Shioyama, Yoshiyuki

AU - Ikawa, Hiroaki

AU - Nemoto, Kenji

AU - Nakano, Takashi

AU - Kamada, Tadashi

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Purpose: To evaluate the safety and efficacy of carbon-ion radiation therapy (C-ion RT) for locally advanced sinonasal malignant tumors in a multicenter retrospective study (J-CROS 1402 HN). Methods and Materials: Clinical data were collected for patients who had sinonasal malignant tumors of stage N0-1M0 and received C-ion RT at 4 institutions in Japan between November 2003 and December 2014. Of the 458 patients, 393 had naïve tumors and 65 had recurrent tumors. The tumors were located in the nasal cavity (n = 263), maxillary sinus (n = 109), ethmoid sinus (n = 71), and other locations (n = 15). The histologic types were mucosal melanoma (n = 221, 48%), adenoid cystic carcinoma (n = 122, 27%), squamous cell carcinoma (n = 31, 7%), olfactory neuroblastoma (n = 30, 7%), adenocarcinoma (n = 21, 5%), and other types (n = 33, 7%). Of the 458 patients, 300 (66%) had T4 tumors. All patients received definitive C-ion RT. Results: The median follow-up period was 25.2 months for all patients (range, 1.4-132.3 months). The 2-year overall survival and local control rates were 79.6% and 84.1%, respectively. As analyzed according to histology, the 2-year overall survival rate was 68.0% for mucosal melanoma, 96.8% for adenoid cystic carcinoma, 70.0% for squamous cell carcinoma, 96.7% for olfactory neuroblastoma, and 89.7% for adenocarcinoma. Regarding late toxicities, 17% of patients developed grade 3 and 4 toxicities, of which visual impairment was the most common. Conclusion: The results of our multicenter study have demonstrated that C-ion RT can provide excellent clinical outcomes with acceptable late toxicities in patients who have locally advanced sinonasal malignant tumors.

AB - Purpose: To evaluate the safety and efficacy of carbon-ion radiation therapy (C-ion RT) for locally advanced sinonasal malignant tumors in a multicenter retrospective study (J-CROS 1402 HN). Methods and Materials: Clinical data were collected for patients who had sinonasal malignant tumors of stage N0-1M0 and received C-ion RT at 4 institutions in Japan between November 2003 and December 2014. Of the 458 patients, 393 had naïve tumors and 65 had recurrent tumors. The tumors were located in the nasal cavity (n = 263), maxillary sinus (n = 109), ethmoid sinus (n = 71), and other locations (n = 15). The histologic types were mucosal melanoma (n = 221, 48%), adenoid cystic carcinoma (n = 122, 27%), squamous cell carcinoma (n = 31, 7%), olfactory neuroblastoma (n = 30, 7%), adenocarcinoma (n = 21, 5%), and other types (n = 33, 7%). Of the 458 patients, 300 (66%) had T4 tumors. All patients received definitive C-ion RT. Results: The median follow-up period was 25.2 months for all patients (range, 1.4-132.3 months). The 2-year overall survival and local control rates were 79.6% and 84.1%, respectively. As analyzed according to histology, the 2-year overall survival rate was 68.0% for mucosal melanoma, 96.8% for adenoid cystic carcinoma, 70.0% for squamous cell carcinoma, 96.7% for olfactory neuroblastoma, and 89.7% for adenocarcinoma. Regarding late toxicities, 17% of patients developed grade 3 and 4 toxicities, of which visual impairment was the most common. Conclusion: The results of our multicenter study have demonstrated that C-ion RT can provide excellent clinical outcomes with acceptable late toxicities in patients who have locally advanced sinonasal malignant tumors.

UR - http://www.scopus.com/inward/record.url?scp=85052247635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052247635&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2018.05.074

DO - 10.1016/j.ijrobp.2018.05.074

M3 - Article

C2 - 30191869

AN - SCOPUS:85052247635

VL - 102

SP - 353

EP - 361

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -